Pivotal studies of pharmacotherapies approved by the US FDA for cancer treatment: a meta-analysis
The Oncologist · 10.04.2026 · 31 (5)
DOI: 10.1093/oncolo/oyag125 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Oncologist, online erschienen am 03.04.2026. Verfasst von Ronald Chow und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Evidence-Based Medicine, University of Oxford, Oxford, OX2 6GG, United Kingdom. Hauptthemen laut MEDLINE: Neoplasms, Drug Approval, Antineoplastic Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
This study aimed to examine the number of FDA-approved cancer pharmacotherapies and analyse pivotal study characteristics over time, including sample sizes.
Methods
We developed a web scraper to collate a cohort of FDA-approved cancer pharmacotherapies from 1953 until 31 December 2024. For each pharmacotherapy, details of pivotal studies leading to approval were recorded, including protocol and final sample size, study design, therapy type, and quality assessment using Cochrane Risk of Bias tools. We used regression analyses and discretization to identify trends in sample size. Type I error was set at 0.05. (Study protocol pre-registration: https://doi.org/10.17605/OSF.IO/KVA23)
Results
We identified 255 pharmacotherapies, supported by 306 pivotal studies; 125 (49%) were targeted pharmacotherapies, 61 (24%) chemotherapies, 47 (18%) immunotherapies, 21 (8%) hormonal therapies, and 1 (0.4%) other. The median sample size was 290 (IQR = 427); sample sizes increased in the 1990s (median = 407) and remained stable thereafter. Stratified analysis demonstrated smaller sample sizes for phase 1 and 2 studies before 1980, with no change in phase 3 studies. For 165 studies reporting protocol sample sizes, studies from 2020-2024 (median = 147.5) were smaller than those from 2010-2019 (median = 320).
Conclusions
The increase in sample sizes during the 1990s may reflect new policies and legislation. Subsequent stability in sample size could be due to modern trial designs (eg, basket/umbrella studies, surrogate endpoints) that require smaller sample sizes. The recent decrease in protocol sample sizes may herald a similar decline for future studies but requires post-market surveillance to verify credibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Evidence-Based Medicine, University of Oxford, Oxford, OX2 6GG, United Kingdom.
- Department of Supportive Care, Princess Margaret Cancer Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, M5G 2M9, Canada.
- Faculty of Medicine & Dentistry, University of Alberta, Edmonton, T6G 2R7, Canada.
- Department of Analytical, Environmental and Forensic Sciences, Institute of Pharmaceutical Sciences, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, SE1 9N…
ORCID-Profile: Ronald Chow, Camilla Zimmermann
Zitieren
APA
Chow, R., Im, J. H. B., Zimmermann, C., Richards, G. C., & Heneghan, C. (2026). Pivotal studies of pharmacotherapies approved by the US FDA for cancer treatment: a meta-analysis. The Oncologist, 31(5). https://doi.org/10.1093/oncolo/oyag125
Vancouver
Chow R, Im JHB, Zimmermann C, Richards GC, Heneghan C. Pivotal studies of pharmacotherapies approved by the US FDA for cancer treatment: a meta-analysis. The Oncologist. 2026;31(5). doi:10.1093/oncolo/oyag125
BibTeX
@article{Chow2026,
author = {Chow, Ronald and Im, James H B and Zimmermann, Camilla and Richards, Georgia C and Heneghan, Carl},
title = {Pivotal studies of pharmacotherapies approved by the US FDA for cancer treatment: a meta-analysis},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {5},
doi = {10.1093/oncolo/oyag125}
}
EUVIMED